Kambi (Buy, TP: SEK210.00) - Improving with sizeable buybacks

The Q3 sales growth was lacklustre YOY due to temporary headwinds, and we have cut our 2025e adj. EPS by 5%. But cash flow is improving (EUR60m net cash at end-Q3); the board announced a EUR12m buyback programme; and the outlook remains positive (customer pipeline, Brazil, efficiency focus and rising shareholder distribution). The negative overreaction on results day has created an attractive opportunity, and we reiterate our BUY and SEK210 target price.

Unwarranted reaction

Solid Q3 with underlying EBIT beat

Oncopeptides (Buy, TP: SEK2.50) - Germany leads Q3 sales miss

Q3 sales were roughly half the level we expected – admittedly from a small base, but still a concern for us, since the miss was led by Germany, with much slower growth than recently. However, operating expenses were also less than we forecast, leaving an operating loss of SEK61m, a fraction better than our cSEK-63m. End-Q3 cash was SEK250m, which the company said would see it to positive cash flow in 2026e. We reiterate our BUY but have cut our target price to SEK2.5 (4.5) on increased uncertainty about the sales ramp up.

Norske Skog (Buy, TP: NOK32.00) - Unfounded concerns

Since the Q3 report that showed that Norske Skog is in good shape in difficult markets, the share price is down c40% on apparent concerns that Norske Skog will become financially distressed. However, after scrutinising the balance sheet and the debt payment structure, we believe the situation is under control. With our earnings forecasts largely intact, we have upgraded to BUY (HOLD) and reiterate our NOK32 target price following the recent share price weakness, in our view based on unfounded concerns and misunderstanding.

Valuation and market update

In this note, we show updated valuation and market statistics for the Offshore Drilling sector.